Rebecca Gilley

928 total citations
14 papers, 723 citations indexed

About

Rebecca Gilley is a scholar working on Molecular Biology, Cell Biology and Oncology. According to data from OpenAlex, Rebecca Gilley has authored 14 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 4 papers in Cell Biology and 3 papers in Oncology. Recurrent topics in Rebecca Gilley's work include Melanoma and MAPK Pathways (8 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and Cellular Mechanics and Interactions (3 papers). Rebecca Gilley is often cited by papers focused on Melanoma and MAPK Pathways (8 papers), Protein Kinase Regulation and GTPase Signaling (4 papers) and Cellular Mechanics and Interactions (3 papers). Rebecca Gilley collaborates with scholars based in United Kingdom, United States and Switzerland. Rebecca Gilley's co-authors include Simon J. Cook, Kathryn Balmanno, Matthew J. Sale, Kate Stuart, Pamela A. Lochhead, H. Nikki March, Katherine Ewings, Ceri M. Wiggins, Julie A. Wickenden and Eileen White and has published in prestigious journals such as Nature Communications, The EMBO Journal and Molecular Cell.

In The Last Decade

Rebecca Gilley

13 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rebecca Gilley United Kingdom 12 564 176 95 94 92 14 723
Andrew M. Kidger United Kingdom 10 543 1.0× 155 0.9× 90 0.9× 82 0.9× 73 0.8× 13 686
Madhavi Bathina United States 8 597 1.1× 183 1.0× 70 0.7× 102 1.1× 98 1.1× 10 771
Lynn Ueno United States 9 630 1.1× 221 1.3× 76 0.8× 148 1.6× 42 0.5× 13 910
Mike I. Walton United Kingdom 7 630 1.1× 283 1.6× 93 1.0× 118 1.3× 56 0.6× 9 856
Ana M. Cosialls Spain 18 601 1.1× 255 1.4× 79 0.8× 99 1.1× 85 0.9× 29 842
Eeva Sommer United Kingdom 6 601 1.1× 90 0.5× 159 1.7× 57 0.6× 179 1.9× 7 817
Carla L. Van Den Berg United States 15 586 1.0× 284 1.6× 64 0.7× 152 1.6× 38 0.4× 18 768
Katayoun I. Amiri United States 11 490 0.9× 318 1.8× 89 0.9× 183 1.9× 41 0.4× 20 746
Shengyong Yang China 15 557 1.0× 109 0.6× 61 0.6× 84 0.9× 68 0.7× 25 713
Daniele Lecis Italy 23 862 1.5× 310 1.8× 90 0.9× 203 2.2× 75 0.8× 49 1.1k

Countries citing papers authored by Rebecca Gilley

Since Specialization
Citations

This map shows the geographic impact of Rebecca Gilley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca Gilley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca Gilley more than expected).

Fields of papers citing papers by Rebecca Gilley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca Gilley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca Gilley. The network helps show where Rebecca Gilley may publish in the future.

Co-authorship network of co-authors of Rebecca Gilley

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca Gilley. A scholar is included among the top collaborators of Rebecca Gilley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca Gilley. Rebecca Gilley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Stuart, Kate, et al.. (2024). Reporter cell lines to screen for inhibitors or regulators of the KRAS-RAF-MEK1/2-ERK1/2 pathway. Biochemical Journal. 481(6). 405–422.
2.
Sale, Matthew J., Kathryn Balmanno, Eiko Ozono, et al.. (2019). MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance. Nature Communications. 10(1). 2030–2030. 41 indexed citations
3.
Walker, Simon, David Oxley, Andrew M. Kidger, et al.. (2019). An mTORC1-to-CDK1 Switch Maintains Autophagy Suppression during Mitosis. Molecular Cell. 77(2). 228–240.e7. 70 indexed citations
4.
Sale, Matthew J., Noel R. Monks, Rebecca Gilley, et al.. (2019). Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors. Nature Communications. 10(1). 5167–5167. 51 indexed citations
5.
Lebraud, Honorine, Rebecca Gilley, Andrew M. Kidger, et al.. (2017). Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe. Bioconjugate Chemistry. 28(6). 1677–1683. 8 indexed citations
6.
Cook, Simon J., Kate Stuart, Rebecca Gilley, & Matthew J. Sale. (2017). Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling. FEBS Journal. 284(24). 4177–4195. 138 indexed citations
7.
Lochhead, Pamela A., Jonathan Clark, Lan-Zhen Wang, et al.. (2016). Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation. Cell Cycle. 15(4). 506–518. 22 indexed citations
8.
Gilley, Rebecca, Kathryn Balmanno, Matthew J. Sale, et al.. (2013). Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. Journal of Cell Science. 127(Pt 4). 788–800. 66 indexed citations
9.
Gilley, Rebecca, et al.. (2013). Adaptation to chronic mTOR inhibition in cancer and in aging. Biochemical Society Transactions. 41(4). 956–961. 11 indexed citations
10.
Lochhead, Pamela A., Rebecca Gilley, & Simon J. Cook. (2012). ERK5 and its role in tumour development. Biochemical Society Transactions. 40(1). 251–256. 60 indexed citations
11.
Gilley, Rebecca, Pamela A. Lochhead, Kathryn Balmanno, et al.. (2011). CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL. Cellular Signalling. 24(1). 170–180. 17 indexed citations
12.
Gilley, Rebecca, H. Nikki March, & Simon J. Cook. (2009). ERK1/2, but not ERK5, is necessary and sufficient for phosphorylation and activation of c-Fos. Cellular Signalling. 21(6). 969–977. 42 indexed citations
13.
Ewings, Katherine, Ceri M. Wiggins, Julie A. Wickenden, et al.. (2007). ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL. The EMBO Journal. 26(12). 2856–2867. 145 indexed citations
14.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew M. Kidger Breakdown of academic impact, for papers by Madhavi Bathina Breakdown of academic impact, for papers by Lynn Ueno Breakdown of academic impact, for papers by Mike I. Walton Breakdown of academic impact, for papers by Ana M. Cosialls Breakdown of academic impact, for papers by Eeva Sommer Breakdown of academic impact, for papers by Carla L. Van Den Berg Breakdown of academic impact, for papers by Katayoun I. Amiri Breakdown of academic impact, for papers by Shengyong Yang Breakdown of academic impact, for papers by Daniele Lecis
Rankless by CCL
2026